Nutriband Inc. (NASDAQ: NTRB) announced on Tuesday the appointment of Robert J. O’Neill to its Advisory Board. O’Neill, a former U.S. Navy SEAL, brings a distinguished military and advocacy background to the pharmaceutical company as it seeks to advance its pipeline of abuse-deterrent transdermal products.
O’Neill served 16 years in the U.S. Navy, including eight years with the Naval Special Warfare Development Group, commonly known as SEAL Team Six. He participated in more than 400 combat missions. Beyond his military service, O’Neill is a New York Times best-selling author and a vocal advocate for expanding veterans’ access to emerging health treatments.
In his advisory role, O’Neill will support Nutriband’s executive team on strategy, growth, and execution as the company progresses its lead product candidate, AVERSA Fentanyl. According to the company, AVERSA Fentanyl would be the world’s first and only abuse-deterrent fentanyl patch if approved. The product incorporates Nutriband’s proprietary AVERSA abuse-deterrent technology, which can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The appointment comes at a critical time for Nutriband, which is primarily engaged in developing a portfolio of transdermal pharmaceutical products. The company’s focus on abuse-deterrent technology addresses a significant public health concern: the potential for misuse of opioid pain medications, including fentanyl. By adding a figure like O’Neill, who has both combat experience and a platform for veterans’ health issues, Nutriband may strengthen its strategic direction and public profile as it navigates regulatory pathways and market positioning.
For investors and industry observers, the move signals Nutriband’s intent to bolster its leadership with diverse expertise. O’Neill’s background in high-stakes environments and his advocacy for veterans could help the company connect with broader stakeholders, including those affected by the opioid crisis. The company’s website, www.nutriband.com, provides additional information about its products and pipeline.
The full press release detailing O’Neill’s appointment is available at https://ibn.fm/WuoNR. Nutriband also maintains a newsroom for the latest updates at https://ibn.fm/NTRB.
The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers services including editorial syndication to 5,000+ outlets and social media distribution to millions of followers. These channels help companies like Nutriband reach a wide audience of investors, journalists, and the general public.
As Nutriband continues to develop its abuse-deterrent technology, the addition of O’Neill to its advisory board could enhance its strategic capabilities and visibility. The company’s success will depend on clinical development, regulatory approvals, and market adoption, but the appointment underscores its commitment to addressing critical health challenges with innovative solutions.
